2. Signaling Pathways
  3. Neuronal Signaling
  4. Glucosylceramide Synthase (GCS)

Glucosylceramide Synthase (GCS)

Glucosylceramide synthase (GCS), converting ceramide to glucosylceramide, catalyzes the first reaction of ceramide glycosylation in sphingolipid metabolism. This glycosylation by GCS is a critical step regulating the modulation of cellular activities by controlling ceramide and glycosphingolipids (GSLs). An increase of ceramide in response to stresses, such as chemotherapy, drives cells to proliferation arrest and apoptosis or autophagy; however, ceramide glycosylation promptly eliminates ceramide and consequently, these induced processes, thus protecting cancer cells. Furthermore, persistently enhanced ceramide glycosylation can increase GSLs, participating in selecting cancer cells to drug resistance. GCS is overexpressed in diverse drug-resistant cancer cells and in tumors of breast, colon, and leukemia that display poor response to chemotherapy. As ceramide glycosylation by GCS is a rate-limiting step in GSL synthesis, inhibition of GCS sensitizes cancer cells to anticancer drugs and eradicates cancer stem cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-16743
    Ibiglustat
    		99.81%
    Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat
  • HY-17020A
    Miglustat hydrochloride
    		Inhibitor 98.20%
    Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease.
    Miglustat hydrochloride
  • HY-17020
    Miglustat
    		Inhibitor ≥98.0%
    Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.
    Miglustat
  • HY-106392
    Lucerastat
    		98.90%
    Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study.
    Lucerastat
  • HY-129411
    Sinbaglustat
    		98.60%
    Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions.
    Sinbaglustat
  • HY-E70184
    α-N-Acetylglucosaminidase
    α-N-Acetylglucosaminidase (EC:3.2.1.50; NAGLU; UFHSD 1) is a alpha-N-acetylglucosaminidase.
    α-N-Acetylglucosaminidase
  • HY-116392B
    DL-threo-PDMP hydrochloride
    		Inhibitor
    DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice.
    DL-threo-PDMP hydrochloride
  • HY-E70157
    Fucosyltransferase 8
    Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT) is a glycosyl transferase and catalyzes the transfer of a fucose residue from GDP-fucose to the innermost N-acetylglucosamine residue of N-glycans.
    Fucosyltransferase 8
  • HY-144267
    Glucosylceramide synthase-IN-2
    		98.45%
    Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research.
    Glucosylceramide synthase-IN-2
  • HY-144266
    TP-060
    		99.83%
    Glucosylceramide synthase-IN-1 (T-036) a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research.
    TP-060
  • HY-116535
    D-threo-PPMP hydrochloride
    		≥98.0%
    D-threo-PPMP hydrochloride is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP hydrochloride can block karyokinesis and reduce cyst production.
    D-threo-PPMP hydrochloride
  • HY-116392D
    PDMP hydrochloride
    		Inhibitor ≥99.0%
    PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research.
    PDMP hydrochloride
  • HY-16743B
    Ibiglustat succinate
    		99.92%
    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat succinate
  • HY-16743A
    Ibiglustat (L-Malic acid)
    		98.07%
    Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat (L-Malic acid)
  • HY-110363
    Miglustat-d9 hydrochloride
    Miglustat-d9 (hydrochloride) is the deuterium labeled Miglustat (hydrochloride). Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1)[1][2].
    Miglustat-d<sub>9</sub> hydrochloride
  • HY-114615
    AMP-Deoxynojirimycin
    		Inhibitor
    AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor.
    AMP-Deoxynojirimycin
  • HY-155715
    G43
    		Inhibitor
    G43 is a potent, selective glucosyltransferase inhibitor, with the Kd of 3.7μM and 46.9 nM for GtfB and GtfC, respectively. G43 has antibacterial to S. mutans in vitro and in vivo, and can be used for dental caries study.
    G43
  • HY-155716
    G43-C3-TEG
    		Inhibitor
    G43-C3-TEG is a glycosyl-transferase inhibitor. G43-C3-TEG reduces the biofilm formation by decreasing the production of EPS (extracellular polysaccharides).
    G43-C3-TEG
  • HY-116392E
    D-threo-PDMP
    		Inhibitor
    D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth.
    D-threo-PDMP
  • HY-148786
    Nizubaglustat
    		Inhibitor
    Nizubaglustat is an inhibitor of Ceramide Glucosyltransferase or Glucosylceramide Synthase (GCS). Nizubaglustat also inhibits GBA2, involving in neuropathological lysosomal storage disorders.
    Nizubaglustat
Cat. No. Product Name / Synonyms Application Reactivity